A phase III trial of higher dose of Qapzola in patients with non-muscle invasive bladder cancer

Trial Profile

A phase III trial of higher dose of Qapzola in patients with non-muscle invasive bladder cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Apaziquone (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2017 According to a Spectrum Pharmaceuticals media release, new study design with a reduced sample size from 1557 to about 425 patients will significantly shorten the duration of this trial.
    • 14 Aug 2017 According to a Spectrum Pharmaceuticals media release, first patient has been enrolled.
    • 14 Aug 2017 Status changed from planning to recruiting, according to a Spectrum Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top